The US could upend biopharma manufacturing. WuXi rivals have an opening

Jared Whitlock

Features Editor

Anna Brown

News Reporter

In Congress, influential lawmakers see a Chinese government threat to the US biotech sector. In the competitive world of biopharma manufacturing, companies see an opportunity …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The US could upend biopharma manufacturing. WuXi rivals have an opening

Jared Whitlock

Features Editor

Anna Brown

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

The US could up­end bio­phar­ma man­u­fac­tur­ing. WuXi ri­vals have an open­ing

Features Editor

News Reporter

Sign up to read this article for free.

The US could upend biopharma manufacturing. WuXi rivals have an opening